11/21
09:10 am
alxo
Bluejay Therapeutics Announces Expansion of Leadership Team and Board of Directors [Yahoo! Finance]
Medium
Report
Bluejay Therapeutics Announces Expansion of Leadership Team and Board of Directors [Yahoo! Finance]
11/14
08:12 am
alxo
ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer [Yahoo! Finance]
Low
Report
ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer [Yahoo! Finance]
11/14
08:00 am
alxo
ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer
Low
Report
ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer
11/12
09:03 am
alxo
ALX Oncology Holdings Inc. (NASDAQ: ALXO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
High
Report
ALX Oncology Holdings Inc. (NASDAQ: ALXO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
11/7
04:00 pm
alxo
ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Medium
Report
ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
11/4
08:00 am
alxo
ALX Oncology Announces November Investor Conference Participation
Neutral
Report
ALX Oncology Announces November Investor Conference Participation
11/1
05:33 pm
alxo
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024 [Yahoo! Finance]
Low
Report
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024 [Yahoo! Finance]
11/1
05:30 pm
alxo
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024
Neutral
Report
ALX Oncology Announces Results from Phase 1b/2 Trial of Evorpacept in Combination with Zanidatamab will be Presented at the San Antonio Breast Cancer Symposium (SABCS) 2024
10/8
05:35 pm
alxo
CD47 Inhibitors Market Projected to Grow Significantly with Emerging Cancer Therapies by 2034 | DelveInsight [Yahoo! Finance]
Medium
Report
CD47 Inhibitors Market Projected to Grow Significantly with Emerging Cancer Therapies by 2034 | DelveInsight [Yahoo! Finance]
9/9
08:00 am
alxo
ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference
Medium
Report
ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference
9/6
07:09 am
alxo
CD47 Inhibitor Drug Clinical Trials Market Outlook to 2028 - Emerging CD47 Inhibitor Clinical Trials Showcase Potential Cancer Treatment Breakthroughs [Yahoo! Finance]
Medium
Report
CD47 Inhibitor Drug Clinical Trials Market Outlook to 2028 - Emerging CD47 Inhibitor Clinical Trials Showcase Potential Cancer Treatment Breakthroughs [Yahoo! Finance]
9/4
08:00 am
alxo
ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi
Medium
Report
ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi